Progress and challenges in anti-obesity pharmacotherapy
Top Cited Papers
- 1 March 2018
- journal article
- review article
- Published by Elsevier BV in The Lancet Diabetes & Endocrinology
- Vol. 6 (3), 237-248
- https://doi.org/10.1016/s2213-8587(17)30236-x
Abstract
No abstract availableThis publication has 111 references indexed in Scilit:
- A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity‐related risk factors (COR‐II)Obesity, 2013
- Controlled‐Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)Obesity, 2012
- Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trialsBMJ, 2012
- The Gut Hormones PYY3-36 and GLP-1(7-36) amide Reduce Food Intake and Modulate Brain Activity in Appetite Centers in HumansCell Metabolism, 2011
- Long-Term Persistence of Hormonal Adaptations to Weight LossNew England Journal of Medicine, 2011
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutideInternational Journal of Obesity, 2011
- U.S. Primary Care Physicians' Diet-, Physical Activity–, and Weight-Related Care of Adult PatientsAmerican Journal of Preventive Medicine, 2011
- The Stigma of Obesity: A Review and UpdateObesity, 2009
- Gut Peptides: Targets for Antiobesity Drug Development?Endocrinology, 2009
- Energy metabolism, fuel selection and body weight regulationInternational Journal of Obesity, 2008